Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
G1 Therapeutics Inc (GTHX)  
$2.56 0.11 (4.12%) as of 4:30 Tue 6/18


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 38,010,000
Market Cap: 97.31(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $1.12 - $4.98
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  935
Guru Rank Value     : 0
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   G1 Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. Co.'s primary compound trilaciclib is a therapy designed to help protect against chemotherapy-induced myelosuppression. Trilaciclib helps protect hematopoietic stem and progenitor cells in the bone marrow by transiently inhibiting CDK4/6 leading to a temporary arrest of susceptible host cells during chemotherapy in patients. Rintodestrant is an oral selective estrogen receptor degrader for the treatment of ER+ breast cancer.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 83,839 178,372 278,007 460,221
Total Sell Value $398,455 $740,302 $990,019 $3,011,511
Total People Sold 7 7 8 10
Total Sell Transactions 7 20 26 43
End Date 2024-03-21 2023-12-19 2023-06-20 2022-06-20

   
Records found: 328
  Page 12 of 14  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Malik Rajesh Ch. Medical Officer & SVP R&D   •       –      –    2018-04-16 4 OE $4.17 $15,746 D/D 3,776 7,976     -
   Velleca Mark A. President and CEO   •       •      –    2018-04-16 4 AS $35.95 $269,971 D/D (7,500) 0     -
   Velleca Mark A. President and CEO   •       •      –    2018-04-16 4 OE $3.72 $27,900 D/D 7,500 7,500     -
   Moses Jennifer K. VP of Finance & Admin   •       –      –    2018-04-05 4 AS $37.47 $28,103 D/D (750) 0     -
   Moses Jennifer K. VP of Finance & Admin   •       –      –    2018-04-05 4 OE $0.39 $293 D/D 750 750     -
   Velleca Mark A. President and CEO   •       •      –    2018-03-15 4 AS $38.20 $286,466 D/D (7,500) 0     -
   Velleca Mark A. President and CEO   •       •      –    2018-03-15 4 OE $3.72 $27,900 D/D 7,500 7,500     -
   Malik Rajesh Ch. Medical Officer & SVP R&D   •       –      –    2018-03-15 4 AS $38.18 $144,151 D/D (3,776) 4,200     -
   Malik Rajesh Ch. Medical Officer & SVP R&D   •       –      –    2018-03-15 4 OE $0.39 $3,348 D/D 3,776 7,976     -
   Malik Rajesh Ch. Medical Officer & SVP R&D   •       –      –    2018-03-08 4 OE $0.39 $1,638 D/D 4,200 4,200     -
   Moses Jennifer K. VP of Finance & Admin   •       –      –    2018-03-05 4 AS $26.55 $19,913 D/D (750) 0     -
   Moses Jennifer K. VP of Finance & Admin   •       –      –    2018-03-05 4 OE $0.39 $293 D/D 750 750     -
   Velleca Mark A. President and CEO   •       •      –    2018-02-15 4 AS $20.00 $150,015 D/D (7,500) 0     -
   Velleca Mark A. President and CEO   •       •      –    2018-02-15 4 OE $3.72 $27,900 D/D 7,500 7,500     -
   Malik Rajesh Ch. Medical Officer & SVP R&D   •       –      –    2018-02-15 4 AS $20.00 $75,520 D/D (3,776) 0     -
   Malik Rajesh Ch. Medical Officer & SVP R&D   •       –      –    2018-02-15 4 OE $0.30 $1,213 D/D 3,776 3,776     -
   Moses Jennifer K. VP of Finance & Admin   •       –      –    2018-02-05 4 AS $22.99 $17,243 D/D (750) 0     -
   Moses Jennifer K. VP of Finance & Admin   •       –      –    2018-02-05 4 OE $0.39 $293 D/D 750 750     -
   Malik Rajesh Ch. Medical Officer & SVP R&D   •       –      –    2018-01-16 4 AS $22.96 $86,693 D/D (3,776) 0     -
   Malik Rajesh Ch. Medical Officer & SVP R&D   •       –      –    2018-01-16 4 OE $0.30 $1,133 D/D 3,776 3,776     -
   Velleca Mark A. President and CEO   •       •      –    2018-01-16 4 AS $22.99 $172,395 D/D (7,500) 0     -
   Velleca Mark A. President and CEO   •       •      –    2018-01-16 4 OE $3.72 $27,900 D/D 7,500 7,500     -
   Moses Jennifer K. VP of Finance & Admin   •       –      –    2018-01-05 4 AS $19.96 $14,970 D/D (750) 0     -
   Moses Jennifer K. VP of Finance & Admin   •       –      –    2018-01-05 4 OE $0.39 $293 D/D 750 750     -
   Velleca Mark A. President and CEO   •       •      –    2017-12-18 4 AS $20.01 $150,106 D/D (7,500) 0     -
  328 Records found
  Previous  10  11  12  13  14   
  Page 12 of 14
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us